查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1209802

全球人用胰島素市場：到 2028 年的預測 - 按產品類型、糖尿病類型、分銷渠道和地區分析

Human Insulin Market Forecasts to 2028 - Global Analysis By Product Type, Diabetes Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球人胰島素市場預計在 2022 年將達到 187 億美元，到 2028 年將達到 248 億美元，預測期內的複合年增長率為 4.7%。 .

人胰島素 (HI) 是一種短效胰島素，用於治療 1 型和 2 型糖尿病引起的高血糖症。 人胰島素是通過基因重組技術生產的，與內源□□性胰島素相同。 通常用作身體製造的胰島素的替代品，它有助於將血液中的糖分結合到其他身體組織並將其用於能量。 胰島素是由胰腺的β細胞產生的一種激素。 在調節葡萄糖水平方面起重要作用。 它調節體內的系統並調節身體細胞對氨基酸的吸收。

根據美國疾病控制和預防中心的數據，20 歲以上的人中約有 160 萬人患有 1 型糖尿病並使用胰島素。 根據亞洲糖尿病預防倡議，由於生活方式和飲食趨勢，亞洲人患糖尿病的風險更高。

市場動態

驅動程序

糖尿病患病率增加

生活方式和飲食的改變顯著增加了患有肥胖症和糖尿病的人口比例。 此外，胰島素製造技術發展顯著，滲透率不斷提高。 胰島素製造技術進步顯著，普及率越來越高。 結果，胰島素變得更便宜，更容易獲得。

抑製劑

成本高

糖尿病患者一生需要頻繁服用胰島素製劑，因此經濟負擔沉重。 由於需要高技能人員和復雜的製造基礎設施，製造成本很高。 胰島素類似物的高成本是製約人胰島素市場增長的主要因素。 此外，胰島素審批的嚴格監管要求也是潛在的製約因素。

機會

增加研發活動的投資

多個組織不斷增加對研發活動的投資，創造了先進而簡單的胰島素注射方法，促進了市場的增長。 此外，更安全的筆型設備和筆型注射針頭用於有效注射胰島素的引入以及糖尿病意識的提高預計將推動需求。 行業領先公司在生物技術領域的醫療保健基礎設施的顯著改善和廣泛的研發活動正在推動市場增長。

威脅

嚴格的規定

藥品審批受到嚴格的監管。 醫療器械法規需要完善，以確保用戶能夠獲得優質、有效和安全的技術。 醫療器械的激增和現代化帶來了新的監管挑戰。 供需關係也開始受到藥物批准所需時間的不利影響。 這些因素將製約人胰島素市場。

COVID-19 的影響

COVID-19 對人胰島素市場產生了反射性影響。 對旅行和貨物流動的限制已對供應鏈造成重大破壞。 此外，為遏制病毒傳播而暫時關閉製造設備也降低了生產率。 結果，全球人胰島素供應出現了短暫但嚴重的短缺。 此外，健康檢查因疫情停業而延期，導致檢測量和試劑銷量下降。 不過，隨著世界各國政府的旅行限制逐漸放寬，檢查數量正在恢復。

胰島素類似物和生物仿製藥有望在預測期內成為最大的

與傳統治療相比，胰島素類似物和生物仿製藥部分由於胰島素效率更高，副作用更少，例如低血糖事件減少和體重增加，預計將實現有利可圖的增長。 堅持治療和血糖控制也很高。 此外，這些產品的銷售和處方率預計在未來幾年內會下降，因為與傳統產品相比，更有效的胰島素類似物的低血糖風險更低。

預計零售和在線藥店在預測期內的複合年增長率最高。

由於疾病負擔的增加、家庭護理患者的可行性以及零售藥店提供的各種折扣，預計零售和在線藥店部分在預測期內將呈現最快的複合年增長率。 網上藥品購買的舒適性、靈活性和便利性是推動這一細分市場的主要因素。 此外，由於在線藥店提供的折扣以及糖尿病患者住院率的增加，患者在線購買藥品的增加也有望推動市場增長。

市場份額最高的地區

由於人口老齡化、生物仿製藥開發研究合作的增加、大公司的地域擴張以及政府和非營利組織進入市場等因素，亞太地區在預測期內將繼續增長。它是預計將佔據最大的市場份額。 此外，針對這種疾病的健康意識運動和科學會議可能會推動該地區的市場增長。

複合年增長率最高的地區

由於人口老齡化、糖尿病患病率上升、醫療保健意識提高、報銷政策改善以及臨床試驗激增等因素，北美將在預測期內實現最高複合年增長率。預測。 此外，主要胰島素製造商的存在、公司之間的激烈競爭以及 1 型糖尿病患病率上升正在推動該地區的增長。

主要發展

2021 年 11 月，Novo Nordisk A/s 收購了 Dicerna Pharmaceuticals，其中包括 Novo Nordisk 用於所有治療領域的研究技術平台，以及 Dicerna 的核糖核酸干擾 (RNAi) 平台。

2021 年 2 月，Biocon Biologics 與國際糖尿病聯合會 (IDF) 合作，成為第一家推動和支持 IDF 重要使命的胰島素生物仿製藥公司。 該合作夥伴關係標誌著胰島素發明 100 週年的開始，並推進了 Biocon Biologics 為全球糖尿病患者提供負擔得起的胰島素的目標。

本報告的內容

  • 區域和國家細分市場份額評估
  • 針對新進入者的戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 涵蓋市場趨勢（市場驅動因素、驅動因素、機遇、威脅、挑戰、投資機會、建議）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局映射主要共同趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 映射最新技術進步的供應鏈趨勢

免費定制服務

訂閱此報告的客戶將免費獲得以下自定義選項之一。

  • 公司簡介
    • 其他市場參與者的綜合概況（最多 3 家公司）
    • 主要參與者的 SWOT 分析（最多 3 家公司）
  • 區域細分
    • 根據客戶要求對主要國家/地區的市場進行估算、預測和復合年增長率（注意：基於可行性檢查。）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球人胰島素市場：產品類型

  • 常規人胰島素
    • 短效生物製劑
    • 中效生物製劑
    • 混合生物製品
  • 胰島素類似物和生物仿製藥
    • 速效生物仿製藥
    • 長效生物類似藥
    • 預混生物仿製藥
  • 其他產品類型

第 6 章全球人胰島素市場：按糖尿病類型分類

  • I 型糖尿病
  • II 型糖尿病
  • 其他類型的糖尿病

第 7 章全球人胰島素市場：按分銷渠道

  • 零售店和在線藥店
  • 醫院藥房
  • 其他分銷渠道

第 8 章全球人胰島素市場：區域

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第九章主要進展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第十章公司簡介

  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Tonghua Dongbao Pharmaceutical Co. Ltd.
  • Julphar
  • Biocon Ltd
  • Sanofi
  • United Laboratories International Holdings Limited
  • Pfizer, Inc.
  • Boehringer Ingelheim International GmbH
  • Wockhardt
  • Bristol-Myers Squibb Company.
  • Oramed Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc.
  • Gan & Lee Pharmaceuticals Co Ltd.
  • Ypsomed AG
  • Shanghai Fosun Pharmaceutical Co., Ltd
Product Code: SMRC22224

According to Stratistics MRC, the Global Human Insulin Market is accounted for $18.7 billion in 2022 and is expected to reach $24.8 billion by 2028 growing at a CAGR of 4.7% during the forecast period. Human insulin (HI) is a short-acting form of insulin used to treat hyperglycemia caused by type-1 and type-2 diabetes. It is produced by recombinant DNA technology and identical to endogenously made insulin. It is used to take the place of insulin generally produced by the body and aids in insulating sugar from the blood into other body tissues, wherein it is utilized for energy. Insulin is a hormone made by the beta cells of the pancreas. It plays a vital role in the regulation of glucose levels. It controls the body's systems and regulates the uptake of amino acids by body cells.

According to the Centers for Disease Control and Prevention, around 1.6 million adults aged 20 years or older have Type 1 diabetes and use insulin. According to the Asian Diabetes Prevention Initiative, people in Asia are at a high risk of developing diabetes due to lifestyle and diet trends.

Market Dynamics:

Driver:

Growing Diabetes Prevalence

The proportion of the population suffering from obesity and diabetes has increased significantly due to change in lifestyle and dietary habits. There has been a remarkable development in insulin production technology which is escalating its adoption rate. Newer technologies like recombinant DNA technology have enabled mass production of insulin to meet the huge demand. Consequently, this has made insulin reasonable and available to reach a wider population.

Restraint:

High cost

The patients suffering from diabetes need to take insulin supplements frequently, forever for their lifetime this puts a financial burden on the individuals. The need for highly skilled manpower and complicated manufacturing infrastructure increases the manufacturing cost. The high cost of insulin analogs is the major factor hindering the human insulin market growth. Furthermore, strict regulatory requirements for insulin approval are also a potential restraining factor.

Opportunity:

Rising Investments in R&D Activities

The rising investments in research and development activities by several organisations have led to an advanced and easier way of injecting insulin, which is boosting the market growth. In addition, the introduction of the safety pen devices and pen needles for effective delivery of insulin, growing awareness of diabetes is expected to bolster the demand. The significant improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of biotechnology conducted by leading industry players are strengthening the growth of the market.

Threat:

Strict regulations

There are severe regulations in place for drug approvals. Medical device regulations must be improved so that users can achieve high-quality, effective, and safe technology. The growing number and modernization of medical devices have led to new regulatory challenges. The demand-supply ratio is also getting adversely affected due to the time taken for approval of drugs. These factors are bound to restrain the human insulin market.

COVID-19 Impact

COVID-19 had a reflective impact on the human insulin market. Due to restrictions in travel and movement of goods, there were wide disruptions in the supply chain. Moreover, the temporary shutdown of manufacturing units to curb the virus spread decreased the production rate. Thus, there was a huge shortage of human insulin worldwide for a short period. Lockdowns arising from the epidemic forced people to put off getting their health checked, reducing the amount of tests performed and reagent sales. However, as governments gradually loosen travel restrictions, there is a rebound in testing numbers.

The insulin analogs and biosimilars segment is expected to be the largest during the forecast period

The insulin analogs and biosimilars segment is estimated to have a lucrative growth, due to the higher efficiency of insulin and minimal adverse effects, such as hypoglycemia attacks and lower weight gain, as compared to conventional therapy. It has better observance to therapy and glycemic control. In addition, it does not pose as much a risk of hypoglycemia compared to traditional products, owing to the presence of more effective insulin analogs, the sales and prescription rate of these products are expected to refuse over the forthcoming years.

The retail & online pharmacies segment is expected to have the highest CAGR during the forecast period

The retail & online pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the rising burden of disease, the feasibility of home care patients, and various discounts offered by retail pharmacies. The comfort, flexibility, and convenience provided by online purchase of medications are major factors driving the segment. In addition, the discounts offered by online pharmacies attract patients to purchase medications online, the rising hospitalization of diabetic patients are also expected to fuel market growth.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to due to factors such as rising geriatric & target populations, increasing number of collaborations for the development of biosimilars, geographic expansion of key players, and active participation of government and non-profit organizations in the market space. Additionally, health awareness campaigns and scientific conferences for the management of this disease may fuel market growth in the region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the factors like growing old age population, rising prevalence of diabetes, increasing healthcare awareness, improvement in reimbursement policies, and surge in clinical trials. The robust presence of the major insulin manufacturers, strong competition among the companies and increasing prevalence of type-1 diabetes are some aspects enhancing the region growth.

Key players in the market

Some of the key players profiled in the Human Insulin Market include Eli Lilly and Company, Novo Nordisk A/S, Tonghua Dongbao Pharmaceutical Co. Ltd., Julphar, Biocon Ltd, Sanofi, United Laboratories International Holdings Limited, Pfizer, Inc., Boehringer Ingelheim International GmbH, Wockhardt, Bristol-Myers Squibb Company., Oramed Pharmaceuticals, Inc., GlaxoSmithKline Plc., Gan & Lee Pharmaceuticals Co Ltd., Ypsomed AG and Shanghai Fosun Pharmaceutical Co., Ltd.

Key Developments:

In November 2021, Novo Nordisk A/s acquired Dicerna Pharmaceuticals, including its Dicerna's ribonucleic acid interference (RNAi) platform, in addition to Novo Nordisk's research technology platforms used across all therapeutic areas.

In February 2021, Biocon Biologics partnered with the International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF's important mission initiative. The collaboration marks the start of the centennial commemoration of the invention of insulin and advances Biocon Biologics' aim of providing inexpensive insulin to individuals with diabetes around the world.

Product Types Covered:

  • Traditional Human Insulin
  • Insulin Analogs and Biosimilars
  • Others Product Types

Diabetes Types Covered:

  • Type I Diabetes
  • Type II Diabetes
  • Other Diabetes Types

Distribution Channels Covered:

  • Retail & Online Pharmacies
  • Hospitals Pharmacies
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Human Insulin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Traditional Human Insulin
    • 5.2.1 Short-Acting Biologics
    • 5.2.2 Intermediate-Acting Biologics
    • 5.2.3 Premixed Biologics
  • 5.3 Insulin Analogs and Biosimilars
    • 5.3.1 Rapid-Acting Biosimilars
    • 5.3.2 Long-Acting Biosimilars
    • 5.3.3 Premix Biosimilars
  • 5.4 Other Product Types

6 Global Human Insulin Market, By Diabetes Type

  • 6.1 Introduction
  • 6.2 Type I Diabetes
  • 6.3 Type II Diabetes
  • 6.4 Other Diabetes Types

7 Global Human Insulin Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail & Online Pharmacies
  • 7.3 Hospitals Pharmacies
  • 7.4 Other Distribution Channels

8 Global Human Insulin Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Eli Lilly and Company
  • 10.2 Novo Nordisk A/S
  • 10.3 Tonghua Dongbao Pharmaceutical Co. Ltd.
  • 10.4 Julphar
  • 10.5 Biocon Ltd
  • 10.6 Sanofi
  • 10.7 United Laboratories International Holdings Limited
  • 10.8 Pfizer, Inc.
  • 10.9 Boehringer Ingelheim International GmbH
  • 10.10 Wockhardt
  • 10.11 Bristol-Myers Squibb Company.
  • 10.12 Oramed Pharmaceuticals, Inc.
  • 10.13 GlaxoSmithKline Plc.
  • 10.14 Gan & Lee Pharmaceuticals Co Ltd.
  • 10.15 Ypsomed AG
  • 10.16 Shanghai Fosun Pharmaceutical Co., Ltd

List of Tables

  • Table 1 Global Human Insulin Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 3 Global Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 4 Global Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 5 Global Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 6 Global Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 7 Global Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 8 Global Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 9 Global Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 10 Global Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 11 Global Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 12 Global Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 13 Global Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 14 Global Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 15 Global Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 16 Global Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 17 Global Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 18 Global Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 19 Global Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 20 North America Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 21 North America Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 22 North America Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 23 North America Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 24 North America Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 25 North America Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 26 North America Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 27 North America Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 28 North America Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 29 North America Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 30 North America Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 31 North America Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 32 North America Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 33 North America Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 34 North America Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 35 North America Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 36 North America Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 37 North America Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 38 North America Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 39 Europe Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 40 Europe Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 41 Europe Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 42 Europe Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 43 Europe Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 44 Europe Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 45 Europe Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 46 Europe Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 47 Europe Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 48 Europe Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 49 Europe Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 50 Europe Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 51 Europe Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 52 Europe Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 53 Europe Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 54 Europe Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 55 Europe Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 56 Europe Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 57 Europe Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 58 Asia Pacific Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 59 Asia Pacific Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 60 Asia Pacific Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 61 Asia Pacific Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 62 Asia Pacific Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 63 Asia Pacific Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 64 Asia Pacific Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 65 Asia Pacific Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 66 Asia Pacific Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 67 Asia Pacific Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 68 Asia Pacific Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 69 Asia Pacific Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 70 Asia Pacific Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 71 Asia Pacific Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 72 Asia Pacific Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 73 Asia Pacific Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 74 Asia Pacific Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 75 Asia Pacific Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 76 Asia Pacific Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 77 South America Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 78 South America Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 79 South America Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 80 South America Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 81 South America Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 82 South America Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 83 South America Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 84 South America Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 85 South America Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 86 South America Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 87 South America Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 88 South America Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 89 South America Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 90 South America Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 91 South America Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 92 South America Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 93 South America Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 94 South America Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 95 South America Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
  • Table 96 Middle East & Africa Human Insulin Market Outlook, By Country (2020-2028) ($MN)
  • Table 97 Middle East & Africa Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
  • Table 98 Middle East & Africa Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
  • Table 99 Middle East & Africa Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
  • Table 100 Middle East & Africa Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
  • Table 101 Middle East & Africa Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
  • Table 102 Middle East & Africa Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
  • Table 103 Middle East & Africa Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
  • Table 104 Middle East & Africa Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
  • Table 105 Middle East & Africa Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
  • Table 106 Middle East & Africa Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
  • Table 107 Middle East & Africa Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
  • Table 108 Middle East & Africa Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
  • Table 109 Middle East & Africa Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
  • Table 110 Middle East & Africa Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
  • Table 111 Middle East & Africa Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 112 Middle East & Africa Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
  • Table 113 Middle East & Africa Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 114 Middle East & Africa Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)